Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 1
2010 1
2011 1
2012 3
2013 7
2014 4
2015 18
2016 15
2017 15
2018 26
2019 12
2020 3
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31019033

97 results

Results by year

Filters applied: . Clear all
Page 1
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J, Kumar S, Un P, Malasani V. Thakral P, et al. Br J Radiol. 2018 Nov;91(1091):20170172. doi: 10.1259/bjr.20170172. Epub 2018 Jul 27. Br J Radiol. 2018. PMID: 30028180 Free PMC article.
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, Michael M, Eu P, Hicks RJ. Kong G, et al. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):476-489. doi: 10.1007/s00259-016-3527-x. Epub 2016 Sep 27. Eur J Nucl Med Mol Imaging. 2017. PMID: 27678267 Clinical Trial.
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, de Herder WW, Krenning EP, Kwekkeboom DJ. Bergsma H, et al. J Nucl Med. 2018 Mar;59(3):452-458. doi: 10.2967/jnumed.117.189712. Epub 2017 Aug 3. J Nucl Med. 2018. PMID: 28775205 Free article.
97 results